FI973118A0 - Lymphotoxin-alpha / beta complexes and antilymphotoxin-beta receptor antibodies as antitumor agents - Google Patents

Lymphotoxin-alpha / beta complexes and antilymphotoxin-beta receptor antibodies as antitumor agents

Info

Publication number
FI973118A0
FI973118A0 FI973118A FI973118A FI973118A0 FI 973118 A0 FI973118 A0 FI 973118A0 FI 973118 A FI973118 A FI 973118A FI 973118 A FI973118 A FI 973118A FI 973118 A0 FI973118 A0 FI 973118A0
Authority
FI
Finland
Prior art keywords
beta
activating agent
lhc
carrier
lymphotoxin
Prior art date
Application number
FI973118A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI119359B (en
FI973118A (en
Inventor
Jeffrey L Browning
Werner Meier
Christopher D Benjamin
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of FI973118A0 publication Critical patent/FI973118A0/en
Publication of FI973118A publication Critical patent/FI973118A/en
Application granted granted Critical
Publication of FI119359B publication Critical patent/FI119359B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A method (A) for treating or reducing the advancement, severity or effects of neoplasia, comprises: administering: (i) a lymphotoxin (LT)-alpha /beta heteromeric complex (LHC) and a carrier, or (ii) >= 1 LT-beta receptor (LT-beta -R) activating agent and a carrier. Also claimed are: (1) a method (B) for selecting a LT-beta -R activating agent which acts in the presence of a LHC, comprising: (a) culturing tumour cells in the presence of LHCs, a first LT-beta -R activating agent and a second putative LT-beta -R activating agent; and (b) determining whether the second putative LT-beta -R activating agent increases the anti-tumour activity of the LHC in the presence of the first LT-beta -R activating agent; (2) a pharmaceutical compsn. comprising an LHC and a carrier; (3) a pharmaceutical compsn. comprising >= 1 LT-beta -R activating agent without exogenous LHC and a carrier, and (4) a pharmaceutical compsn. comprising cross-linked anti-LT-beta -R antibodies as a LT-beta -R activating agent and a carrier.
FI973118A 1995-01-26 1997-07-25 Lymphotoxin-alpha / beta complexes and antilymphotoxin-beta receptor antibodies as antitumor agents FI119359B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37896895A 1995-01-26 1995-01-26
US37896895 1995-01-26
US9601386 1996-01-26
PCT/US1996/001386 WO1996022788A1 (en) 1995-01-26 1996-01-26 LYMPHOTOXIN-α/β COMPLEXES AND ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS

Publications (3)

Publication Number Publication Date
FI973118A0 true FI973118A0 (en) 1997-07-25
FI973118A FI973118A (en) 1997-09-25
FI119359B FI119359B (en) 2008-10-31

Family

ID=23495285

Family Applications (1)

Application Number Title Priority Date Filing Date
FI973118A FI119359B (en) 1995-01-26 1997-07-25 Lymphotoxin-alpha / beta complexes and antilymphotoxin-beta receptor antibodies as antitumor agents

Country Status (25)

Country Link
EP (2) EP1407781A1 (en)
JP (2) JPH10513161A (en)
KR (2) KR100470739B1 (en)
CN (3) CN1900116A (en)
AT (1) ATE268604T1 (en)
AU (1) AU725351B2 (en)
BG (1) BG62599B1 (en)
BR (1) BR9606808A (en)
CA (1) CA2211443A1 (en)
CZ (1) CZ298711B6 (en)
DE (1) DE69632681T2 (en)
DK (1) DK0809510T3 (en)
EA (1) EA000096B1 (en)
EE (1) EE04453B1 (en)
ES (1) ES2220972T3 (en)
FI (1) FI119359B (en)
HK (1) HK1006356A1 (en)
HU (1) HUP9801746A3 (en)
NO (1) NO322744B1 (en)
NZ (1) NZ303405A (en)
PL (1) PL185364B1 (en)
PT (1) PT809510E (en)
RO (1) RO118634B1 (en)
SK (1) SK286497B6 (en)
WO (1) WO1996022788A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7118742B2 (en) * 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
DE69931944T2 (en) 1998-10-09 2007-02-08 Biogen Idec Ma Inc., Cambridge REVERSE OF VIRAL-INDUCED SYSTEMIC SHOCKS AND RESPIRATORY SYNDROME THROUGH BLOCKING OF THE LYMPHOTOXIN BETA ACTIVATION PATH
CA2425809A1 (en) 2000-10-13 2002-04-18 Biogen, Inc. Humanized anti-lt-.beta.-r antibodies
EP1539793A4 (en) * 2002-07-01 2006-02-01 Humanized anti-lymphotoyin beta receptor antibodies
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
PL377611A1 (en) * 2002-12-20 2006-02-06 Biogen Idec Ma Inc. Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
EP1756162A1 (en) 2004-03-23 2007-02-28 Biogen Idec MA Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP1764371A1 (en) * 2005-04-25 2007-03-21 Xantos Biomedicine AG Agonist antibodies that bind to the LT-beta receptor, thereby modulating adiposity-associated phenotypes, and their use in therapy
CN101073665B (en) * 2006-05-17 2014-11-26 上海复旦张江生物医药股份有限公司 Use of lymphotoxin in treatment of medicine for increasing chemoradiotherapeutic sensitivity
EP2067041A2 (en) 2006-10-03 2009-06-10 Biogen Idec MA, Inc. Biomarkers and assays for the treatment of cancer
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
KR20090071652A (en) 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 Treatment of demyelinating disorders with soulble lymphotoxin-beta-receptor
BRPI0913687A2 (en) * 2008-09-30 2015-10-13 Genentech Inc predictive biological markers of rheumatoid arthritis response to lymphotoxin antagonists
CA2857398A1 (en) * 2011-12-05 2013-06-13 Igenica Biotherapeutics, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
EP3750918A1 (en) 2015-01-20 2020-12-16 IGM Biosciences, Inc. Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6124599A (en) * 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd Novel human interferon-gamma polypeptide derivative
JPS61277628A (en) * 1985-06-04 1986-12-08 Asahi Chem Ind Co Ltd Lymphocyte-stimulation material for remedy of cancer
US4770995A (en) * 1985-08-29 1988-09-13 New York Blood Center, Inc Detection of the sensitivity of cells to the effects of tumor necrosis factor and lymphotoxin
AU692146B2 (en) * 1990-06-27 1998-06-04 Biogen Idec Ma Inc. Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preparations and therapeutic uses thereof
ES2157889T3 (en) * 1990-06-27 2001-09-01 Biogen Inc COMPLEX SURFACE LYMPHOTOXIN.

Also Published As

Publication number Publication date
DE69632681T2 (en) 2005-06-09
KR100470739B1 (en) 2005-09-02
CN1589902A (en) 2005-03-09
SK286497B6 (en) 2008-11-06
HK1006356A1 (en) 1999-02-26
MX9705629A (en) 1997-10-31
EE04453B1 (en) 2005-04-15
PL321758A1 (en) 1997-12-22
PT809510E (en) 2004-09-30
NO973385L (en) 1997-09-25
EA000096B1 (en) 1998-08-27
EA199700144A1 (en) 1997-12-30
WO1996022788A1 (en) 1996-08-01
CN1146442C (en) 2004-04-21
CZ298711B6 (en) 2008-01-02
NZ303405A (en) 2000-02-28
BR9606808A (en) 1997-12-30
SK98697A3 (en) 2000-02-14
JP2007169296A (en) 2007-07-05
KR100475492B1 (en) 2005-03-14
DK0809510T3 (en) 2004-10-04
FI119359B (en) 2008-10-31
HUP9801746A2 (en) 1998-11-30
EE9700255A (en) 1998-04-15
RO118634B1 (en) 2003-08-29
CA2211443A1 (en) 1996-08-01
BG62599B1 (en) 2000-03-31
EP0809510B1 (en) 2004-06-09
AU4970496A (en) 1996-08-14
CN1177302A (en) 1998-03-25
ES2220972T3 (en) 2004-12-16
CZ236197A3 (en) 1998-02-18
KR19980701816A (en) 1998-06-25
CN1900116A (en) 2007-01-24
KR20040102364A (en) 2004-12-04
EP0809510A1 (en) 1997-12-03
DE69632681D1 (en) 2004-07-15
AU725351B2 (en) 2000-10-12
PL185364B1 (en) 2003-04-30
NO322744B1 (en) 2006-12-04
ATE268604T1 (en) 2004-06-15
FI973118A (en) 1997-09-25
BG101855A (en) 1998-04-30
NO973385D0 (en) 1997-07-22
JPH10513161A (en) 1998-12-15
EP1407781A1 (en) 2004-04-14
HUP9801746A3 (en) 2000-11-28

Similar Documents

Publication Publication Date Title
FI973118A0 (en) Lymphotoxin-alpha / beta complexes and antilymphotoxin-beta receptor antibodies as antitumor agents
Wang et al. Advancing to the era of cancer immunotherapy
Aragane et al. Involvement of dectin-2 in ultraviolet radiation-induced tolerance
DE69841164D1 (en) SPHINGOSINE-1-PHOSPHATE LYASE POLYPEPTIDES, POLYNUCLEOTIDES AND MODULATING AGENTS, AND METHOD FOR THEIR USE
MX9709324A (en) THERAPEUTIC COMPOUNDS COMPRISED OF ANTI-Fc RECEPTOR ANTIBODIES.
YU83600A (en) Adenosine a3 receptor modulators
EP0734264A4 (en) Compositions that specifically bind to colorectal cancer cells and methods of using the same
AU2332188A (en) Compounds having antiprogestational and anti-estrogenic activities for the treatment of hormone-dependent tumors
IL128003A0 (en) Therapeutic multispecific compounds comprised of anti-fcalpha receptor antibodies
KIRKPATRICK et al. Stereospecific glucocorticoid binding to subcellular fractions of the sensitive and resistant lymphosarcoma P1798
NO20003552L (en) Progesterone agonist compounds, pharmaceutical compositions containing them and the use of the compound, as well as a method for determining the presence of steroid receptors, ligand-steroid receptor complexes and a method
EP0330201A3 (en) Method of enhancing the effect of cytotoxic agents
IL127558A0 (en) Hepatocyte growth factor receptor agonists and uses thereof
KR950002784A (en) Methods for determining lymph nodes enriched in tumor responsive cells, methods for proliferation thereof, and methods for use in adoptive cell therapy
WO1995034320A3 (en) Methods for inhibiting antigen specific t cell responses
AU2739188A (en) Novel antibodies
UA42806C2 (en) System for the simultaneous trans-dermal introduction of several active agents
GR3025698T3 (en) NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES.
WO1997041225A3 (en) Mammalian mixed lymphocyte receptors, chemokine receptors [mmlr-ccr]
WO1995016709A3 (en) Anti-mullerian hormone receptor polypeptides and antibodies thereto
WO2002053195A3 (en) System for, and method of, irradiating article with x-ray beam
Rubin et al. A minimal toxicity approach to cancer therapy: possible role of beta-glucuronidase
DK0943014T3 (en) Methods for diagnosing glaucoma and detecting antiglaucoma drugs
Andres et al. Phylogenetic disparity influences the predominance of direct over indirect pathway of antigen presentation in islet xenotransplantation
NO965347L (en) Method for Preparation of Cytolytic T Cells Specific to a Peptide / MHC Complex

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: BIOGEN IDEC MA INC.

Free format text: BIOGEN IDEC MA INC.

FG Patent granted

Ref document number: 119359

Country of ref document: FI